The novel medication, Retatrutide, is creating growing excitement in the UK for a possible treatment for obesity. Created by Eli Lilly, this medicine merges the actions of several GLP-1 receptor agonists and an GIP receptor agonist, seeking to more effectively impact appetite and boost energy expenditure. Preliminary clinical trials have indicated